Blog | HemaCare

HemaCare Leukopaks Employed for Development of Bi-Specific Antibodies for Cancer Immunotherapy

Mar 26, 2019 10:09:00 AM / by Nancy Andon, MSc posted in Cancer Immunology, cancer immunotherapy, cytotoxic T cells, T cells, monoclonal antibody

0 Comments

Scientists at antibody engineering company Xencor in Monrovia, CA have just published a research paper that cites using HemaCare sourced leukopaks in the development of their new antibody platform. 

Monoclonal antibody therapy has become central to the treatment of many different diseases, including autoimmune disorders, asthma and cancer. Yet in spite of this success, many disease targets have yet to be effectively addressed. Monoclonal antibodies have trouble binding to antigens that are weakly expressed, which results in a need for higher dosing concentrations. High treatment dosages, in turn, can lead to toxicity effects. Monoclonals are also limited in that they can only block one target at a time, leaving parallel disease pathways open that can lead to treatment resistance.

Read More

Versatility and Specificity of CAR-T Cell Cytokines

Dec 13, 2017 8:43:54 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer Immunology, cancer immunotherapy, immunotherapy, Peripheral Blood Mononuclear Cell

0 Comments

In chimeric antigen receptor (CAR)-T cell immunotherapy, T cells are obtained from a patient and genetically modified to express specific receptors (CARs) against tumor antigens. The best studied and successful CAR-T cells target the CD19 antigen on neoplastic B cells. However, this targeted approach gives quite variable results. The secretion by CD19 CAR-T cells of various cell signaling molecules varies between patients and individual CAR-T cells. The question then is how to measure the ability of CD19 CAR-T cells to release signals, after a specific antigenic challenge and correlate that to patient responses.

Read More

CAR-T: The Designer Tumor Therapy Frontier

Dec 4, 2017 8:00:25 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer Immunology, cancer immunotherapy, CAR T cells, car

0 Comments

Personalized medicine is taking new and powerful forms in the field of immunotherapy. The technology behind making customized tumor-destroying cells, thought of not long ago as science-fiction, is now a reality. [1,2] Chimeric Antigen Receptor T cells, or CAR-T cells, are designer, precision built personal immunotherapeutic agents that target an individual’s tumor. The use of CAR-T cells is a means of using the body’s own immune system arsenal to attack cancer cells.

Read More

Fasting to Starve Cancer Cells

Sep 6, 2016 4:44:14 PM / by Stacy Matthews Branch, DVM, PhD posted in fasting, Cancer Immunology, cytotoxic T cells, fasting chemotherapy, research

0 Comments

The ancient and well-known practice of fasting is simply the avoidance of food intake for a specific time period. This practice has religious and health-related basis. It is thought that fasting allows the system to reset, which can help prevent cancer cell survival. It has been shown over the years that fasting often has a beneficial anti-cancer effect.

Read More

Getting personal with your cancer therapy

Aug 3, 2016 3:35:05 AM / by Stacy Matthews Branch, DVM, PhD posted in cancer, Cancer Immunology, cancer immunotherapy, cell therapy, clinical trial, Innovation

0 Comments

For many years, cancer therapy has been tackled with a more or less universal approach. The drawback of this approach to therapy is the wide range of different responses to a given therapy. The concept of personalized medicine, tailoring treatment to a patient’s specific characteristics, has been envisioned and desired for many years. It is now being studied and implemented to increase successful responses to therapy, including cancer therapy.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts